Need a Pfizer COVID-19 vaccine? Find a primary care doctor near you >

Showing 1 - 10 of 28 Other
Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >

A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Aldona Spiegel

Study Coordinator:

Phone:

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Status: Enrolling

Investigator: Monisha Singh

Study Coordinator: Caroline Fitzgerald

Phone: 713.441.3250

NGM120 is an experimental drug made by NGM Biopharmaceuticals, Inc. NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve ... Read more >

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease. ... Read more >

A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

Status: Enrolling

Investigator: David Victor

Study Coordinator:

Phone:

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH). ... Read more >

A Registry for Patients Taking Uptravi (SPHERE)

Status: Open Not Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into t ... Read more >

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease. Participants will take either TAK-018 or placebo tablets by mouth, 2 times each day for up t ... Read more >

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease. ... Read more >

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response (LoR) to subcut ... Read more >

A011-09 PULSAR A Phase 2 Study of Sotatercept for the Treatment of PAH

Status: Open Not Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

Study A011-09 is a Phase 2, double-blind, randomized, placebo-controlled, multicenter, parallel-group study to determine the efficacy and safety of sotatercept (ACE-011) plus standard of care (SOC) versus placebo plus SOC in adults with pulmonar ... Read more >

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease. ... Read more >

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

The purpose of this study is to compare the incidence of lymphoma in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi versus those treated with thiopurines. ... Read more >

Corrona Inflammatory Bowel Disease (IBD) Registry

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >

GORE® TAG® Thoracic Branch Endoprosthesis

Status: Enrolling

Investigator: Marvin Atkins

Study Coordinator: Kim Donlon

Phone: 713.441.9394

This study is a prospective, multicenter, non-randomized single-arm study to assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® TAG® Thoracic Branch Endoprosthesis system. ... Read more >

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease. ... Read more >

NMDA Receptor in Psychosis: Specific Auto-Antibodies

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Rejani Nair

Phone: 346.238.0083

Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N- ... Read more >

Ocrelizumab for Psychosis by Autoimmunity (OPA)

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Rejani Nair

Phone: 346.238.0083

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to at ... Read more >

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

This open-label extension and safety monitoring study is composed of two parts: Part 1 will evaluate the long-term safety and efficacy of continued etrolizumab treatment in participants with moderately to severely active Crohn's disease who were ... Read more >

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso (BREEZE)

Status: Open Not Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Royanne Holy

Phone: 713.363.7536

United Therapeutics Corporation (UTC) is developing a combination drug-device product which is comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and ... Read more >

PIANO

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator:

Phone:

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part ... Read more >

Pulmonary Hypertension Association Registry (PHAR)

Status: Open Not Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in part ... Read more >

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >

Supraspinal Targets in Voiding Dysfunction

Status: Enrolling

Investigator: Rose Khavari

Study Coordinator:

Phone:

Difficulty in bladder emptying (Voiding dysfunction,VD) is a costly urinary condition that leads to urinary tract infections/stones, sepsis, bladder loss, and permanent kidney damage. VD can be present in patients with or without neurologic/brai ... Read more >

The MARE Study

Status: Open Not Enrolling

Investigator: Neal Kleiman

Study Coordinator:

Phone:

The purpose of this study is to determine the incidence and predictors of high degree or complete atrioventricular block (AVB) (paroxysmal or persistent) in patients with new-onset persistent left bundle branch block (NOP-LBBB) following transca ... Read more >

X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP)

Status: Enrolling

Investigator: Dale Hamilton

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of buro ... Read more >